Perhaps a better question to ask is what might Dendreon have been worth if the FDA had been behind advancing the first immune therapy for cancer instead of against it...?...A treatment I might ad eventually will save the government, tax payers and patients money and quality of life and length of life.
Case in point...not Dendreon.
<<In other words, this is a decision that hurts everyone's pocketbook – not just those of Amylin's shareholders.
We've talked before about Joseph Tainter and his study of the downfall of civilizations in the past. You may recall his argument that complex societies tend to collapse when the layers of complexity and their costs rise faster than the energy supply. We doubt Tainter would have used Amylin as a case study, but the parallels seem clear to us. As the business of healthcare becomes bogged down by ineffective and expensive layers of bureaucracy, to the point that they exceed the benefits of finding new treatments, the whole system runs the danger of collapsing.>>
Who's pocket book did AMLN's non approvable letter in October of 2010 benefit...?
The entire article...
The tail of woe is not just the Dendreon story, is it...?
I would ask, and perhaps Casey would say, Looks like our Dendreon birth right is being stolen...?